Journal of Medical Toxicology

, Volume 9, Issue 2, pp 196–198 | Cite as

Recurrent Seizures and Serotonin Syndrome Following “2C-I” Ingestion

Toxicology Observation

Abstract

The phenethylamines, including 2, 5 dimethoxy-4-iodophenethylamine, commonly referred to as 2C-I, have recently emerged as a new class of designer drugs. Cases of toxicity from these drugs are not well described in the literature. This case report describes a 19 year-old male who insufflated 2C-I. Following the ingestion, the patient developed recurrent seizures, and was taken to the emergency department, where he was noted to be hyperadrenergic and had recurrent seizures. The patient was diagnosed with serotonin syndrome and experienced prolonged respiratory failure, although he ultimately made a full recovery. Comprehensive drug testing revealed the presence of 2C-I. The pharmacologic properties of 2C-I are also discussed.

Keywords

Serotonin syndrome 2C-I 2CI Phenethylamine Seizure Rave 

Notes

Disclosures

There are no financial, litigational, or other conflicts of interest to disclose.

References

  1. 1.
    Haroz R, Greenberg MI (2005) Emerging drugs of abuse. Med Clin N Am 89:1259–76PubMedCrossRefGoogle Scholar
  2. 2.
    Andreasen MF, Telving R, Birkler RI et al (2009) A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 183:91–6PubMedCrossRefGoogle Scholar
  3. 3.
    Theobald DS, Pütz M, Schneider E et al (2006) New designer drug 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic-mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J Mass Spectrom 41:872–86PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson MP, Mathis CA, Shuligin AT et al (1990) [125I]-2-(2, 5-Dimethoxy-4-iodophenyl)aminoethane ([125]-2C-I) as a label for the 5HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav 35:211–7PubMedCrossRefGoogle Scholar
  5. 5.
    Castillo AC, Villalobos C, Moya PR et al (2002) Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5HT2A and 5HT2C receptors. Br J Pharmacol 136:510–9CrossRefGoogle Scholar
  6. 6.
    Nagai F, Nonaka R, Satoh Hisashi Kamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132–7PubMedCrossRefGoogle Scholar
  7. 7.
    Maurer HH (2010) Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit 32:544–9PubMedCrossRefGoogle Scholar
  8. 8.
    Theobald DS, Maurer HH (2007) Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2c-series). Biochem Pharmacol 73:287–97PubMedCrossRefGoogle Scholar
  9. 9.
    Drug Enforcement Administration, Office of Forensic Sciences. Microgram Bulletin. US Department of Justice, Drug Enforcement Administration. 2004; 38:48-9Google Scholar
  10. 10.
    DeBoer D, Gijzeles MJ, Bosman IJ et al (1999) More data about the new psychoactive drug 2C-B. J Anal Toxicol 23:227–8CrossRefGoogle Scholar
  11. 11.
    Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352:1112–20PubMedCrossRefGoogle Scholar
  12. 12.
    Dunkey EJ, Isbister GK, Sibbritt D et al (2003) The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96:635–42CrossRefGoogle Scholar
  13. 13.
    Kirshner R, Donovan JW (2010) Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med 38:477–80CrossRefGoogle Scholar

Copyright information

© American College of Medical Toxicology 2013

Authors and Affiliations

  1. 1.Department of Medical ToxicologyBanner Good Samaritan Medical CenterPhoenixUSA
  2. 2.Department of Emergency Medicine, Section of Medical ToxicologyUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations